Intercytex summary February 2006



Bridgehead International provides Experts’ Report for listing of Intercytex Group plc on AIM

Intercytex Group plc announced on 1st February 2006 that it had successfully completed an initial public offering on the AIM market of the London Stock Exchange, raising £15 million. The placing was conducted by Piper Jaffray Ltd., acting as sole broker and nominated advisor. Intercytex is an emerging healthcare company using its proprietary cell therapy technology to build woundcare and aesthetic medicine businesses.

Bridgehead International carried out independent due diligence on behalf of Intercytex Group plc and Piper Jaffray in the form of what is known as the 'Experts' Report', which was published in the Listing Document.

The publication of a report such as this satisfies regulatory requirements in certain cases, but it is the process leading up to its preparation that adds real value. Bridgehead’s expert consultants review many aspects of the Company's technical and commercial operations and, during the process, the Company and its Advisors gain an insight into concerns that potential investors are likely to have. The Company then has the opportunity, in advance of publication of the prospectus, either to take action to avoid these potential concerns or to have available the information or plans to address them.

Bridgehead is widely recognised as the leading provider of independent reports to support fundraising in the pharmaceutical and medical device fields in the UK, it has also worked with companies raising finance in the USA, Scandinavia and the Far East. Some of the companies that Bridgehead has reviewed as part of stock market listings and other investment rounds are: AGI Therapeutics plc, Lombard Medical plc, Vectura Group plc, Inion Ltd, ProStrakan Group plc, Alizyme plc Cardiomag Imaging Inc, GeneMedix plc, GW Pharmaceuticals plc, Akers Bioscience Inc and CustomVis plc.

Top